Inhibition of Rat Urinary Bladder Carcinogenesis by the Antiangiogenic Drug TNP-470


Potential inhibitory effects of the antiangiogenic drug TNP-470 on rat urinary bladder carcinogenesis were ‍investigated in F344 male rats initiated with 0.05% BBN in the drinking water for 8 weeks. Group 1 was then ‍continuously treated with TNP-470 by subcutaneous injection using osmotic minipump until the end of the experiment; ‍group 2 served as the control with only initiation. The incidences and multiplicities of papillomas and carcinomas in ‍the TNP-470-treated group were significantly decreased compared to the control group values along with the tumor ‍vascular density. In conclusion, TNP-470 can inhibit rat urinary bladder carcinogenesis, presumably through its ‍effects on angiogenesis.